Clinical trials located in

Bellaria – Igea Marina

Bellaria - Igea Marina city is located in Italy. Currently, 5 clinical trials are being conducted in this city.

Bellaria – Igea Marina, nestled along the Adriatic coast in Italy, is a unique blend of natural beauty and historical charm. This city, divided by the Uso River, offers a picturesque landscape with its sandy beaches and lush greenery. It has a rich history dating back to Roman times, evident in its ancient architecture and archaeological sites. The city is renowned for its vibrant cultural scene, hosting numerous festivals and events that celebrate its heritage and community spirit. Bellaria – Igea Marina also takes pride in its commitment to environmental sustainability, boasting several eco-friendly initiatives.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • Study of the safety and effectiveness of the new drug -TAK-861 in the treatment of narcolepsy

    The clinical trial includes patients with narcolepsy. Patients will be given a drug called TAK-861. The aim of the study is to assess the safety and tolerability of TAK-861, as well as its effect on the symptoms of narcolepsy, including excessive daytime sleepiness and the number of cataplexy episodes. Cataplexy is sudden muscle weakness caused by strong emotions, e.g. laughter.

    The study will involve up to 160 patients who previously participated in controlled studies with TAK-861. Patients will be assigned to one of the treatment groups based on the dose they received in the previous study. All patients participating in this study will receive TAK-861.

    The study will last approximately 108 weeks. Patients will need to visit the clinic regularly, although some visits may take place at home. After completing the drug administration, they will undergo a 4-week observation period.

    • TAK-861

See more clinical trials in other cities in Italy: